Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects

David K. Simon, Tanya Simuni, Jordan Elm, Joanne Clark-Matott, Allison K. Graebner, Liana Baker, Susan R. Dunlop, Marina Emborg, Cornelia Kamp, John Christopher Morgan, G. Webster Ross, Saloni Sharma, Bernard Ravina

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.

Original languageEnglish (US)
Pages (from-to)731-736
Number of pages6
JournalJournal of Parkinson's Disease
Issue number4
StatePublished - Nov 21 2015


  • 8-hydroxydeoxyguanosine
  • 8OHdG
  • IL-6
  • PGC-1alpha
  • Parkinsons disease
  • biomarker
  • cytokine
  • inflammation
  • interleukin-6
  • oxidativestress
  • pioglitazone

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects'. Together they form a unique fingerprint.

Cite this